EPCAM and neoplasm: Hampel et al. report failure of MLPA deletion analysis in approximately 15% of patients with MSI-positive tumours.2 Weissman et al. note that some MLPA kits for detection of MSH2 deletions also encompass possible EPCAM deletions57 but data on the performance of this or other MLPA tests for EPCAM deletions (including the commercial MS-MLPA kit which can be used to detect methylation of the MSH2 promoter)67 are not available.